A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors
Latest Information Update: 24 Jul 2025
At a glance
- Drugs INCB 099280 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Incyte Corporation
Most Recent Events
- 08 Jan 2025 Status changed from active, no longer recruiting to completed.
- 01 Nov 2024 Planned End Date changed from 31 Oct 2025 to 31 Dec 2024.
- 04 Jun 2024 Results assessing safety, efficacy and pharmacokinetics were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.